Bio-techne Corp. has agreed to spend up to $325 million on an acquisition that represents the company's entry into the genomics market. Bio-techne said it will pay $250 million in cash for Advanced Cell Diagnostics (ACD) plus another $75 million tied to the achievement of certain milestones. Read More
